{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:58:09Z","timestamp":1771930689760,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was founded by the Shenyang Municipal Public Health Research and Development Special Project in 2020.","award":["20-205-4-094, BC"],"award-info":[{"award-number":["20-205-4-094, BC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare disease characterized by atypical symptoms, difficult diagnosis, variable course and poor prognosis, and it develops mainly in elderly individuals. The authors aimed to identify the clinical-pathological characteristics, prognosis, and prognostic factors in elderly MPM patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From the National Cancer Institute Surveillance Epidemiology End Results (SEER) database, 1492 patients with MPM from 1975 to 2016 were selected and divided into the elderly group (\u2265\u200965) and the adult group (&lt;\u200965). We compared the clinical-pathological characteristics and treatment methods of the elderly group (N\u2009=\u2009665) and the adult group (N\u2009=\u2009827). At the same time, we analysed specific selected clinicopathological parameters and prognostic factors for elderly MPM patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the adult group, the elderly group had higher percentages of male patients (<jats:italic>P<\/jats:italic>\u2009=\u20090.017) and white patients (<jats:italic>P<\/jats:italic>\u2009=\u20090.043) and lower proportions of insured patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) married patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), patients with peritoneal tumours (<jats:italic>P<\/jats:italic>\u2009=\u20090.006) and patients who underwent surgery (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and chemotherapy (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). There was a significant difference in the differentiation grade between the two groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.003). Elderly patients had a shorter median survival time than adult patients (6\u00a0months vs. 19\u00a0months). Uninsured (hazard ratio (HR): 5.187, <jats:italic>P<\/jats:italic>\u2009=\u20090.005), sarcomatoid type (HR 3.913, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), poorly differentiated (HR 3.900, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), distant metastasis (HR 1.735, <jats:italic>P<\/jats:italic>\u2009=\u20090.001), no cancer-directed surgery (HR 1.733, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and no chemotherapy (HR 1.532, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were independently associated with poorer prognosis in elderly MPM patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with adult patients, elderly MPM patients had a higher male ratio, poor differentiation and relatively conservative treatment. The cancer-specific survival (CSS) rate of elderly MPM patients was significantly lower than that of adult patients. Insurance status, histology type, differentiation grade, stage, surgery status, and chemotherapy status were all independent prognostic factors for elderly MPM patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02361-3","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T16:16:44Z","timestamp":1654791404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly"],"prefix":"10.1186","volume":"22","author":[{"given":"Dan","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wencheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixuan","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"issue":"2","key":"2361_CR1","first-page":"32","volume":"9","author":"A Bridda","year":"2007","unstructured":"Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007;9(2):32.","journal-title":"MedGenMed"},{"issue":"5\u20136","key":"2361_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/10937404.2016.1195323","volume":"19","author":"RA Lemen","year":"2016","unstructured":"Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev. 2016;19(5\u20136):250\u201365.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"8","key":"2361_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","volume":"66","author":"JM Mazurek","year":"2017","unstructured":"Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality\u2014United States, 1999\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2361_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/path.1700120212","volume":"12","author":"J Miller","year":"1908","unstructured":"Miller J, Wynn WH. A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid. J Pathol Bacteriol. 1908;12:267\u201378.","journal-title":"J Pathol Bacteriol"},{"issue":"2","key":"2361_CR5","first-page":"302","volume":"8","author":"M Yano","year":"2018","unstructured":"Yano M, Ikeda Y, Kato T, et al. A case of peritoneal malignant mesothelioma following radiation therapy for cervical cancer. Mol Clin Oncol. 2018;8(2):302\u20135.","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"2361_CR6","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","volume":"21","author":"JT Miura","year":"2014","unstructured":"Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21(12):3947\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2361_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control. 2009;20(6):935\u201344.","journal-title":"Cancer Causes Control"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"2782590","DOI":"10.1155\/2017\/2782590","volume":"2017","author":"R Shavelle","year":"2017","unstructured":"Shavelle R, Vavra-Musser K, Lee J, Brooks J. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:2782590.","journal-title":"Lung Cancer Int"},{"issue":"4","key":"2361_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4149\/neo_2014_053","volume":"61","author":"H Kaya","year":"2014","unstructured":"Kaya H, Sezg\u0131 C, Tanr\u0131kulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 2014;61(4):433\u20138.","journal-title":"Neoplasma"},{"issue":"18","key":"2361_CR10","doi-asserted-by":"publisher","first-page":"16766","DOI":"10.18632\/oncotarget.4414","volume":"6","author":"A Thomas","year":"2015","unstructured":"Thomas A, Chen Y, Yu T, Gill A, Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;6(18):16766\u201373.","journal-title":"Oncotarget"},{"issue":"3","key":"2361_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/oemed-2015-103309","volume":"73","author":"MJ Soeberg","year":"2016","unstructured":"Soeberg MJ, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982\u20132009. Occup Environ Med. 2016;73(3):187\u201394.","journal-title":"Occup Environ Med"},{"issue":"1","key":"2361_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jso.21167","volume":"99","author":"D Rodr\u00edguez","year":"2009","unstructured":"Rodr\u00edguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99(1):51\u20137.","journal-title":"J Surg Oncol"},{"key":"2361_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canep.2019.03.014","volume":"60","author":"FRANCIM network; MESOPATH Referent National Center","year":"2019","unstructured":"FRANCIM network; MESOPATH Referent National Center. Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: a population-based study. Cancer Epidemiol. 2019;60:106\u201311.","journal-title":"Cancer Epidemiol"},{"issue":"15","key":"2361_CR14","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140\u20138.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2361_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander Jr","year":"2013","unstructured":"Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779\u201386.","journal-title":"Surgery"},{"issue":"4","key":"2361_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21(4):1159\u201365.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2361_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5(11):236.","journal-title":"Ann Transl Med"},{"issue":"36","key":"2361_CR18","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2361_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.21873\/anticanres.13183","volume":"39","author":"SAS Salo","year":"2019","unstructured":"Salo SAS, Ilonen I, Laaksonen S, Myll\u00e4rniemi M, Salo JA, Rantanen T. Malignant peritoneal mesothelioma: treatment options and survival. Anticancer Res. 2019;39(2):839\u201345.","journal-title":"Anticancer Res"},{"key":"2361_CR20","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. overview of the SEER program. https:\/\/seer.cancer.gov\/data\/."},{"issue":"15","key":"2361_CR21","first-page":"393","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","unstructured":"Centers for Disease Control and Prevention (CDC). Malignant mesothelioma mortality\u2014United States, 1999\u20132005. MMWR Morb Mortal Wkly Rep. 2009;58(15):393\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/2156-7514.135662","volume":"4","author":"B Singhal","year":"2014","unstructured":"Singhal B, Kohli S, Singhal A, Kumar V. Malignant pleural and peritoneal mesothelioma consequential to brief indirect asbestos exposure. J Clin Imaging Sci. 2014;4:35.","journal-title":"J Clin Imaging Sci"},{"issue":"18","key":"2361_CR23","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ejca.2007.09.018","volume":"43","author":"Italian Mesothelioma Register (ReNaM) Working Group","year":"2007","unstructured":"Italian Mesothelioma Register (ReNaM) Working Group. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer. 2007;43(18):2722\u20138.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2361_CR24","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/annonc\/mdr477","volume":"23","author":"Peritoneal Surface Malignancy Group","year":"2012","unstructured":"Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23(6):1494\u20138.","journal-title":"Ann Oncol"},{"key":"2361_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canep.2017.10.008","volume":"51","author":"SAS Salo","year":"2017","unstructured":"Salo SAS, Ilonen I, Laaksonen S, Myll\u00e4rniemi M, Salo JA, Rantanen T. Epidemiology of malignant peritoneal mesothelioma: a population-based study. Cancer Epidemiol. 2017;51:81\u20136.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"2361_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/annonc\/mdp307","volume":"21","author":"VP Manzini","year":"2010","unstructured":"Manzini VP, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21(2):348\u201353.","journal-title":"Ann Oncol"},{"issue":"41","key":"2361_CR27","doi-asserted-by":"publisher","first-page":"70204","DOI":"10.18632\/oncotarget.19600","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H, Wang L, Kabirov I, et al. Impact of marital status on renal cancer patient survival. Oncotarget. 2017;8(41):70204\u201313.","journal-title":"Oncotarget"},{"issue":"49","key":"2361_CR28","doi-asserted-by":"publisher","first-page":"86157","DOI":"10.18632\/oncotarget.21029","volume":"8","author":"T Miao","year":"2017","unstructured":"Miao T, Li Y, Sheng X, Yao D. Marital status and survival of patients with kidney cancer. Oncotarget. 2017;8(49):86157\u201367.","journal-title":"Oncotarget"},{"issue":"2","key":"2361_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13524-011-0032-5","volume":"48","author":"MS Rendall","year":"2011","unstructured":"Rendall MS, Weden MM, Favreault MM, Waldron H. The protective effect of marriage for survival: a review and update. Demography. 2011;48(2):481\u2013506.","journal-title":"Demography"},{"issue":"9","key":"2361_CR30","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"Peritoneal Surface Oncology Group","year":"2011","unstructured":"Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117(9):1855\u201363.","journal-title":"Cancer"},{"issue":"11","key":"2361_CR31","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/jjco\/hyz104","volume":"49","author":"Y Nagata","year":"2019","unstructured":"Nagata Y, Sawada R, Takashima A, et al. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Jpn J Clin Oncol. 2019;49(11):1004\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"2361_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"French Network for Rare Peritoneal Malignancies (RENAPE)","year":"2016","unstructured":"French Network for Rare Peritoneal Malignancies (RENAPE). Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69\u201379.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2361_CR33","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1245\/s10434-018-6337-5","volume":"25","author":"HR Alexander Jr","year":"2018","unstructured":"Alexander HR Jr, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol. 2018;25(8):2159\u201364.","journal-title":"Ann Surg Oncol"},{"issue":"4 Suppl","key":"2361_CR34","first-page":"41","volume":"22","author":"M Deraco","year":"2003","unstructured":"Deraco M, De Simone M, Rossi CR, et al. An Italian multicentric phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res. 2003;22(4 Suppl):41\u20135.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2361_CR35","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2361_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jso.21177","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99(2):109\u201313.","journal-title":"J Surg Oncol"},{"issue":"Suppl 1","key":"2361_CR37","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","volume":"9","author":"A Greenbaum","year":"2020","unstructured":"Greenbaum A, Alexander HR. Peritoneal mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S120\u201332.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"2361_CR38","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2361_CR39","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","volume":"19","author":"D Baratti","year":"2012","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416\u201324.","journal-title":"Ann Surg Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02361-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T16:17:59Z","timestamp":1654791479000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02361-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02361-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"12 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study complied with the Declaration of Helsinki. All analysis were based on the Surveillance Epidemiology End Results (SEER), a public database and provides de-identified case data, thus no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}